EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures

Kerstin Walter iD, Lindsey H M Te Brake, Ann-Kathrin Lemm, Michael Hoelscher, Elin M Svensson, Christoph Hölscher, Norbert Heinrich iD

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Kerstin Walter und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infection Immunology, Research Center Borstel, Leibniz Lung Center, Borstel, Germany. Hauptthemen laut MEDLINE: Nitroimidazoles, Antitubercular Agents, Diarylquinolines, Mice, Inbred BALB C. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Center for Infection Research, PanACEA 2, German Ministry for Education and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

New and shorter regimens against multi-drug resistant tuberculosis (TB) remain urgently needed. To inform treatment duration in clinical trials, this study aimed to identify human pharmacokinetic equivalent doses, antimycobacterial and sterilizing activity of a novel regimen, containing bedaquiline, delamanid, moxifloxacin and sutezolid (BDMU), in the standard mouse model (BALB/c) of Mycobacterium tuberculosis (Mtb) infection.

Methods

Treatment of mice with B25D0.6M200U200, B25D0.6M200, B25D0.6M200(U2003) or H10R10Z150E100 (isoniazid, rifampicin, pyrazinamide, ethambutol, HRZE), started 3 weeks after Mtb infection. Bactericidal activity was assessed after 1, 2, 3 and 4 months of treatment and relapse rates were assessed 3 months after completing treatment durations of 2, 3 and 4 months.

Results

B25D0.6M200U200 generated human equivalent exposures in uninfected BALB/c mice. After 1 month of treatment, a higher bactericidal activity was observed for the B25D0.6M200U200 and the B25D0.6M200 regimen compared to the standard H10R10Z150E100 regimen. Furthermore, 3 months of therapy with both BDM-based regimens resulted in negative lung cultures, whereas all H10R10Z150E100 treated mice were still culture positive. After 3 months of therapy 7% and 13% of mice relapsed receiving B25D0.6M200U200 and B25D0.6M200, respectively, compared to 40% for H10R10Z150E100 treatment showing an increased sterilizing activity of both BDM-based regimens.

Conclusions

BDM-based regimens, with and without sutezolid, have a higher efficacy than the HRZE regimen in the BALB/c model of TB, with some improvement by adding sutezolid. By translating these results to TB patients, this novel BDMU regimen should be able to reduce treatment duration by 25% compared to HRZE therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitroimidazolesAntitubercular AgentsDiarylquinolinesMice, Inbred BALB CDisease Models, AnimalMycobacterium tuberculosisOxazolesMoxifloxacinDrug Therapy, CombinationAnimalsMiceFemaleTuberculosis, Multidrug-ResistantOxazolidinonesPyrazinamideTreatment OutcomeIsoxazoles

Substanzen

NitroimidazolesbedaquilineAntitubercular AgentsDiarylquinolinesOPC-67683OxazolesMoxifloxacinOxazolidinonesPyrazinamideterizidone

Autor:innen und Institutionen

  • Division of Infection Immunology, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
  • German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.
  • Department of Pharmacy, Radboud Institute of Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Institute of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany.
  • German Center for Infection Research, Partner Site Munich, Munich, Germany.
  • Fraunhofer Institute ITMP, Immunology, Infection and Pandemic Research, Munich, Germany.

ORCID-Profile: Kerstin Walter, Norbert Heinrich

Förderung

  • German Center for Infection Research
  • PanACEA 2
  • German Ministry for Education and Research
  • Swiss State Secretariat for Education, Research, and Innovation
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Zitieren

APA

Walter, K., Te Brake, L. H. M., Lemm, A. K., Hoelscher, M., Svensson, E. M., Hölscher, C., & Heinrich, N. (2024). Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae266

Vancouver

Walter K, Te Brake LHM, Lemm AK, Hoelscher M, Svensson EM, Hölscher C, et al. Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae266

BibTeX
@article{Walter2024,
  author = {Walter, Kerstin and Te Brake, Lindsey H M and Lemm, Ann-Kathrin and Hoelscher, Michael and Svensson, Elin M and Hölscher, Christoph and Heinrich, Norbert},
  title = {Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae266}
}
Kostenlos starten →